Main content
PD-1/PD-L1 inhibitors versus chemotherapy in advanced non-small cell lung cancer with negative PD-L1 expression: a meta-analysis of randomized controlled trials
Date created: | Last Updated:
: DOI | ARK
Creating DOI. Please wait...
Category: Analysis
Description: It is a systematic review and meta-analysis of fourteen contemporary phase II and phase III trials evaluating outcomes following PD-1/PD-L1 inhibitor therapy (immunotherapy-exclusive or chemotherapy-immunotherapy combination regimens) in locally advanced and metastatic NSCLC with < 1% PD-1 expression. This particular subset of patients makes up 50-60% of advanced NSCLC patients for whom the optimal therapy regimen is yet to be defined. In addition, histologic subtypes and lines of treatment further complicate the treatment strategy.
Start managing your projects on the OSF today.
Free and easy to use, the Open Science Framework supports the entire research lifecycle: planning, execution, reporting, archiving, and discovery.